Dublin-listed Open Orphan has reported that its first volunteer has been dosed in an intranasal Covid-19 vaccine clinical trial.
The volunteer was treated with the Codagenix needle free, intranasal Covid-19 vaccine called COVI-VAC.
COVI-VAC is a single-dose vaccine against SARS-CoV-2, the virus that causes Covid-19. It contains the entire virus in a weakened form.
The clinical trial is being conducted by Open Orphan subsidiary Hvivo at its London facility.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).